Randomized clinical trial of BCG vaccine in patients with convalescent COVID-19: Clinical evolution, adverse events, and humoral immune response.

ABSTRACT:

Background

The Bacillus Calmette-Guérin (BCG) vaccine may confer cross-protection against viral diseases in adults. This study evaluated BCG vaccine cross-protection in adults with convalescent coronavirus disease 2019 (COVID-19).

Method

This was a multicenter, prospective, randomized, placebo-controlled, double-blind phase III study (ClinicalTrials.gov: NCT04369794).

Setting

University Community Health Center and Municipal Outpatient Center in South America.

Patients

a total of 378 adult patients with convalescent COVID-19 were included.

Intervention

single intradermal BCG vaccine (n = 183) and placebo (n = 195).

Measurements

the primary outcome was clinical evolution. Other outcomes included adverse events and humoral immune responses for up to

SUBMITTER: Jalalizadeh M 

PROVIDER: S-EPMC9347570 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature